William Blair Brokers Raise Earnings Estimates for Twist Bioscience Co. (NASDAQ:TWST)

Twist Bioscience Co. (NASDAQ:TWST) – Research analysts at William Blair boosted their Q1 2025 earnings per share estimates for Twist Bioscience in a research note issued to investors on Monday, June 17th. William Blair analyst M. Larew now expects that the company will post earnings per share of ($0.69) for the quarter, up from their previous estimate of ($0.71). The consensus estimate for Twist Bioscience’s current full-year earnings is ($3.08) per share. William Blair also issued estimates for Twist Bioscience’s Q2 2025 earnings at ($0.63) EPS, Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.54) EPS and FY2025 earnings at ($2.44) EPS.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.05. The company had revenue of $75.30 million during the quarter, compared to the consensus estimate of $70.70 million. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. Twist Bioscience’s revenue was up 25.1% compared to the same quarter last year. During the same quarter last year, the business posted ($1.06) earnings per share.

Other analysts have also issued reports about the company. TD Cowen boosted their price objective on Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, June 13th. Scotiabank upped their target price on Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a report on Monday, May 6th. Robert W. Baird upped their target price on Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. Guggenheim initiated coverage on Twist Bioscience in a report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 price objective for the company. Finally, Barclays increased their price objective on Twist Bioscience from $40.00 to $45.00 and gave the stock an “overweight” rating in a report on Friday, May 3rd. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $46.63.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $50.56 on Wednesday. Twist Bioscience has a fifty-two week low of $14.42 and a fifty-two week high of $55.26. The stock has a fifty day moving average of $40.79 and a two-hundred day moving average of $37.17.

Institutional Trading of Twist Bioscience

A number of hedge funds have recently modified their holdings of the business. Federated Hermes Inc. acquired a new stake in shares of Twist Bioscience in the third quarter worth $29,000. EdgeRock Capital LLC acquired a new stake in shares of Twist Bioscience in the fourth quarter worth $30,000. Headlands Technologies LLC acquired a new stake in shares of Twist Bioscience in the first quarter worth $124,000. International Assets Investment Management LLC boosted its position in shares of Twist Bioscience by 3,519.8% in the fourth quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock worth $148,000 after buying an additional 3,907 shares during the period. Finally, Brown Advisory Inc. acquired a new stake in shares of Twist Bioscience in the fourth quarter worth $225,000.

Insider Activity

In other news, insider William Banyai sold 798 shares of the stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total transaction of $29,629.74. Following the completion of the sale, the insider now owns 345,188 shares in the company, valued at approximately $12,816,830.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider William Banyai sold 798 shares of the stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total transaction of $29,629.74. Following the completion of the sale, the insider now owns 345,188 shares in the company, valued at approximately $12,816,830.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Emily M. Leproust sold 2,408 shares of the stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $51.33, for a total value of $123,602.64. Following the sale, the chief executive officer now owns 507,578 shares of the company’s stock, valued at approximately $26,053,978.74. The disclosure for this sale can be found here. In the last 90 days, insiders sold 17,163 shares of company stock worth $666,151. Insiders own 3.92% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.